Skip to main content
. 2017 Apr 4;317(13):1321–1328. doi: 10.1001/jama.2017.2088

Table 1. Participant Characteristics.

Characteristics Dexmedetomidine Group
(n = 100)
Control Group
(n = 101)
Age, mean (SD), y 68 (14.9) 69 (13.6)
Male, No. (%) 63 (63) 64 (63)
Body weight, mean (SD), kg 55 (12.5) 58 (15.3)
COPD, No. (%) 8 (8) 9 (9)
Soft tissue infection, No. (%) 8 (8) 10 (10)
Emergency surgery, No. (%) 37 (37) 36 (36)
Renal replacement therapy, No. (%) 22 (22) 20 (20)
APACHE II score, median (IQR)a 23 (18-29) 22 (16-29.5)
SOFA scores, median (IQR)b
Overall score 8 (6-11) 9 (5-11)
Respiratory score 2 (1-3) 2 (1-3)
Circulatory score 3 (2-4) 3 (1.5-4)
Renal score 1 (0-2) 1 (0-3)
Hepatic score 0 (0-1) 0 (0-1)
Neurological score 1 (0-2) 0 (0-3)
Coagulation score 0 (0-2) 1 (0-2)
Shock, No. (%)c 71 (71) 68 (67)
Lactate level, median (IQR), mmol/Ld 3.7 (2.1-5.4) 3.3 (1.8-5.4)
C-reactive protein, median (IQR), mg/dL 13.8 (6.0-25.7) 16.8 (6.4-25.8)
Procalcitonin, median (IQR), ng/mL 15.2 (2.8-44.9) 14.6 (1.5-81.5)
Comorbidities, No. (%)
Immunocompromised 16 (16) 15 (15)
Chronic hemodialysis 7 (7) 7 (7)
Chronic respiratory disorder 4 (4) 5 (5)
Chronic heart failure 2 (2) 2 (2)
Liver insufficiency 1 (1) 1 (1)
Site of infection, No. (%)
Abdomen 39 (39) 35 (35)
Thorax 39 (39) 33 (33)
Urinary tract 6 (6) 10 (10)
Pancreatitis 3 (3) 9 (9)
Skin and soft tissue 6 (6) 7 (7)
Central nervous system 1 (1) 1 (1)
Others 6 (6) 6 (6)

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment.

a

The APACHE II score ranges from 0 to 71, with higher scores indicating more severe disease.

b

The SOFA score ranges from 0 to 24, with higher scores indicating more severe disease.

c

Shock was defined as having 3 or more cardiovascular components of the SOFA score.

d

Serum lactate level was missing for 3 patients.